[CA 125 in the diagnosis and evaluation of the efficacy of the treatment of cancer of the ovaries].
The paper is concerned with the results of CA-125 radioimmunoassay in 163 patients (584 tests) with benign and malignant ovarian diseases and other small pelvic diseases which were diagnosed before operation as ovarian tumors. CA-125 radioimmunoassay can be used in combination with other methods for investigation of patients with suspected ovarian cancer and for differential diagnosis of malignant ovarian tumors to distinguish them from other malignant tumors of the small pelvis. The total accuracy of the method, its sensitivity and specificity were 94.6%, 96.9 and 93.2%, respectively. CA-125 levels were considerably increased in malignant ovarian tumors irrespective of their histological structure. The investigation of CA-125 indices in the course of disease was indicative of the effectiveness of antitumor therapy.
Sagan
D L
DL
Chebotareva
E D
ED
Evtushenko
G V
GV
D000230:Adenocarcinoma / Q000276:immunology / Q000628:therapy; D000328:Adult; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis*; D003131:Combined Modality Therapy; D003536:Cystadenocarcinoma / Q000276:immunology / Q000628:therapy; D003537:Cystadenoma / Q000276:immunology / Q000628:therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000276:immunology / Q000628:therapy*; D011379:Prognosis; D011863:Radioimmunoassay
D015295:Antigens, Tumor-Associated, Carbohydrate
CA 125 dlia diagnostiki i otsenki éffektivnosti terapii raka iachnikov.